The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin

被引:61
作者
Rakotoniaina, Zo
Guerard, Pascal
Lirussi, Frederic
Goirand, Francoise
Rochette, Luc
Dumas, Monique
Bardou, Marc
机构
[1] LPPCE Fac Med, F-21079 Dijon, France
[2] Univ Burgundy, Lab Expt Cardiovasc Physiopathol & Pharmacol, EA2979, F-21000 Dijon, France
关键词
reductase inhibitors; pravastatin; atorvastatin; pulmonary arterial hypertension;
D O I
10.1007/s00210-006-0112-z
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, so called statins, improve endothelial function and exert antiproliferative effects on vascular smooth muscle cells of systemic vessels. This study aimed at comparing the protective effects of two statins, pravastatin and atorvastatin, against monocrotaline ( MC)-induced pulmonary hypertension in rats. Pravastatin or atorvastatin ( PS or AS, 10 mg/kg per day) or vehicle were given orally for 28 days to Wistar male rats injected or not with MC ( 60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed severe pulmonary hypertension, with an increase in right ventricular pressure (RVP) and right ventricle/left ventricle + septum weight ratio associated with a decrease in acetylcholine-or sodium-nitroprusside-induced pulmonary artery dilation observed in vitro. Hypertensive pulmonary arteries exhibited an increase in medial thickness and endothelial cell apoptosis and a decrease of endothelial nitric oxide synthase ( eNOS) expression. MC-rat lungs showed a significant decrease of eNOS ( P < 0.01) and increase of cleaved caspase-3 (P < 0.05) expression determined by Western blotting. PS (P = 0.02) but not AS (P = 0.30) significantly limited the development of pulmonary hypertension ( RVP in mmHg: 30 +/- 3, 36 +/- 4 vs. 45 +/- 4 and 14 +/- 1 for MC + PS, MC + AS, MC, and control groups, respectively). Both statins significantly reduced MC-induced right ventricle hypertrophy [RV/left ventricular (LV) + S, in mg/g: 0.46 +/- 0.04, 0.39 +/- 0.03, 0.62 +/- 0.05 and 0.29 +/- 0.01 for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05), and reduced MC-induced thickening ( 61 +/- 6 mu m, 82 +/- 5 mu m, 154 +/- 4 mu m, and 59 +/- 2 mu m for MC + PS, MC + AS, MC, and control groups, respectively; P= 0.01) of small intrapulmonary artery medial wall, with MC + AS still being different from the control group. PS but not AS partially restored acetylcholine-induced pulmonary artery vasodilation in MC rats (E-max 65 +/- 5%, 49 +/- 6%, 46 +/- 3%, and 76 +/- 4% for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05 for MC + PS vs. other groups). Both statins prevented apoptosis and restored eNOS expression of pulmonary artery endothelial cells as well as in the whole lung with a more pronounced effect with PS compared with AS. In conclusion, despite its effects on eNOS expression, apoptosis, and medial wall thickening, AS was unable to significantly reduce pulmonary hypertension and to restore endothelium-dependent relaxation, suggesting intermolecular differences between the two HMG-CoA reductase inhibitors in the protection against MC-induced hypertension.
引用
收藏
页码:195 / 206
页数:12
相关论文
共 52 条
[1]
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells [J].
Baetta, R ;
Donetti, E ;
Comparato, C ;
Calore, M ;
Rossi, A ;
Teruzzi, C ;
Paoletti, R ;
Fumagalli, R ;
Soma, MR .
PHARMACOLOGICAL RESEARCH, 1997, 36 (02) :115-121
[2]
Hypoxic vasoconstriction of rat main pulmonary artery: Role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition [J].
Bardou, M ;
Goirand, F ;
Marchand, S ;
Rouget, C ;
Devillier, P ;
Dumas, JP ;
Morcillo, EJ ;
Rochette, L ;
Dumas, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 38 (02) :325-334
[3]
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].
Barst, Robyn J. ;
Langleben, David ;
Badesch, David ;
Frost, Adaani ;
Lawrence, E. Clinton ;
Shapiro, Shelley ;
Naeije, Robert ;
Galie, Nazzareno .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056
[4]
How valid are animal models to evaluate treatments for pulmonary hypertension? [J].
Campian, Maria E. ;
Hardziyenka, Maxim ;
Michel, Martin C. ;
Tan, Hanno L. .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 373 (06) :391-400
[5]
Dobrucki L W, 2001, Med Sci Monit, V7, P622
[6]
Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload [J].
Ecarnot-Laubriet, A ;
Assem, M ;
Poirson-Bichat, F ;
Moisant, M ;
Bernard, C ;
Lecour, S ;
Solary, E ;
Rochette, L ;
Teyssier, JR .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1586 (03) :233-242
[7]
Ecarnot-Laubriet Aline, 2003, Heart Dis, V5, P308, DOI 10.1097/01.hdx.0000089836.03515.a9
[8]
Endo Hirahito, 2004, Nihon Rinsho Meneki Gakkai Kaishi, V27, P127
[9]
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS [J].
Guerard, Pascal ;
Rakotoniaina, Zo ;
Goirand, Francoise ;
Rochette, Luc ;
Dumas, Monique ;
Lirussi, Frederic ;
Bardou, Marc .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 373 (06) :401-414
[10]
Clinical pharmacokinetics of pravastatin - Mechanisms of pharmacokinetic events [J].
Hatanaka, T .
CLINICAL PHARMACOKINETICS, 2000, 39 (06) :397-412